SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH
₹459.2905
₹3.83 (-0.83%)
NAV as of 31 May 2026
Today's NAV — all variants
Regular · Growth
₹₹459.2905
₹3.83 (-0.83%)
31 May 2026
AMFI: 102823
Direct · Growth
₹₹530.5772
₹4.36 (-0.82%)
31 May 2026
AMFI: 119783
Regular · IDCW
₹₹289.3287
₹2.41 (-0.83%)
31 May 2026
AMFI: 100644
Direct · IDCW
₹₹368.6293
₹3.03 (-0.82%)
31 May 2026
AMFI: 119782
Returns (Lumpsum)
CAGR for periods ≥ 1 yearSIP Returns (XIRR)
₹1,000/month SIP, annualisedSIP since inception — what ₹500/month became
Real NAV backtest from day one
₹1,28,500
Invested
₹9,34,110
Value today
16.0%
XIRR (p.a.)
₹500/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹5,000 lumpsum at launch — value today
Invested on the fund's first NAV date
₹5,000
Invested
₹1,03,959
Value today
15.2%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹10L corpus with ₹5,000/month withdrawals since inception
Corpus is still growing despite monthly payouts
₹10,00,000
Initial corpus
₹12,85,000
Withdrawn
₹1,14,50,687
Corpus left
+₹1,17,35,687 net gain — withdrew ₹12,85,000 AND corpus grew
Plan your SWP with real NAV₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹1,24,75,070
Value today
+0.0%
vs lumpsum
STP beat direct lumpsum by 0.0% — reduced timing risk paid off
Model your own STP with real NAVBeat the benchmark — ₹500/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹9,34,110
Benchmark
₹6,24,479
+₹3,09,631 extra wealth vs the benchmark index
Backtest this SIP yourself₹1 lakh on the worst crash day — 22 Mar 2020
Worst single-day Nifty drop during this fund's life
₹1,00,000
Invested
₹4,46,864
Value today
4.5×
Multiple
Staying invested through that crash turned ₹1L into ₹4,46,864 — a 4.5× return
Read: Staying invested through crashesDirect vs Regular — ₹500/month over 10 years
Expense ratio drag on your actual returns
Direct plan
₹1,64,423
Regular plan
₹1,53,840
Direct earns ₹10,583 more on a ₹60K investment — 1.76% extra return per year
Same fund, same NAV history — only the expense ratio differs. Direct plans always outperform Regular over time.
Learn about Direct vs Regular plansFund Details
Risk Metrics
Trailing 1 year, annualised0.05
Sharpe Ratio
+0.05
Alpha
0.29
Beta
0.05
Sortino
13.99%
Std Dev
-13.63%
Max Drawdown
Portfolio Holdings
Top 50 holdings · as of Mar 2026
| Security | % NAV |
|---|---|
Sun Pharmaceutical Industries Ltd. INE044A01036 | 1211.00% |
Sun Pharmaceutical Industries Ltd. INE044A01036 | 1171.00% |
Divi's Laboratories Ltd. INE361B01024 | 677.00% |
Divi's Laboratories Ltd. INE361B01024 | 659.00% |
Acutaas Chemicals Ltd. INE00FF01025 | 567.00% |
Apollo Hospitals Enterprise Ltd. INE437A01024 | 548.00% |
Acutaas Chemicals Ltd. INE00FF01025 | 540.00% |
Apollo Hospitals Enterprise Ltd. INE437A01024 | 530.00% |
Max Healthcare Institute Ltd. INE027H01010 | 517.00% |
Max Healthcare Institute Ltd. INE027H01010 | 497.00% |
Lupin Ltd. INE326A01037 | 410.00% |
Aster DM Healthcare Ltd. INE914M01019 | 396.00% |
Aster DM Healthcare Ltd. INE914M01019 | 389.00% |
Lupin Ltd. INE326A01037 | 384.00% |
Torrent Pharmaceuticals Ltd. INE685A01028 | 374.00% |
Aether Industries Ltd. INE0BWX01014 | 356.00% |
Torrent Pharmaceuticals Ltd. INE685A01028 | 348.00% |
Anthem Biosciences Ltd. INE0CZ201020 | 345.00% |
Aether Industries Ltd. INE0BWX01014 | 335.00% |
Mankind Pharma Ltd. INE634S01028 | 333.00% |
Biocon Ltd. INE376G01013 | 333.00% |
Aurobindo Pharma Ltd. INE406A01037 | 321.00% |
Fortis Healthcare Ltd. INE061F01013 | 320.00% |
Anthem Biosciences Ltd. INE0CZ201020 | 317.00% |
Mankind Pharma Ltd. INE634S01028 | 316.00% |
Biocon Ltd. INE376G01013 | 312.00% |
Laurus Labs Ltd. INE947Q01028 | 306.00% |
Lonza Group US54338V1017 | 297.00% |
Laurus Labs Ltd. INE947Q01028 | 293.00% |
Fortis Healthcare Ltd. INE061F01013 | 293.00% |
Jupiter Life Line Hospitals Ltd. INE682M01012 | 284.00% |
Lonza Group US54338V1017 | 271.00% |
Alkem Laboratories Ltd. INE540L01014 | 261.00% |
Aurobindo Pharma Ltd. INE406A01037 | 257.00% |
Jupiter Life Line Hospitals Ltd. INE682M01012 | 255.00% |
Gland Pharma Ltd. INE068V01023 | 250.00% |
Alkem Laboratories Ltd. INE540L01014 | 250.00% |
Krishna Institute of Medical Sciences Ltd. INE967H01025 | 247.00% |
Sai Life Sciences Ltd. INE570L01029 | 247.00% |
Krishna Institute of Medical Sciences Ltd. INE967H01025 | 245.00% |
Gland Pharma Ltd. INE068V01023 | 243.00% |
Sai Life Sciences Ltd. INE570L01029 | 224.00% |
Polymedicure Ltd. INE205C01021 | 224.00% |
Sudeep Pharma Ltd. INE0QPI01025 | 223.00% |
Ajanta Pharma Ltd. INE031B01049 | 207.00% |
Sudeep Pharma Ltd. INE0QPI01025 | 198.00% |
Ajanta Pharma Ltd. INE031B01049 | 196.00% |
Abbott India Ltd. INE358A01014 | 191.00% |
| Security | % NAV |
|---|---|
TREPS | 336.00% |
TREPS | 268.00% |
Performance Comparison
Interested in This Fund?
Our experts will help you decide if this fund fits your goals.
Compare with Similar Funds
Investment Objective
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH is a Sectoral / Thematic mutual fund offered by SBI Mutual Fund. The fund has been operational for over 26 years. It manages assets worth ₹3,979 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE TRI. The current expense ratio is 1.93%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations